Supplementary Figure S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer

Nolan-Stevaux, Olivier; Li, Cong; Liang, Lingming; Zhan, Jinghui; Estrada, Juan; Osgood, Tao; Li, Fei; Zhang, Hanzhi; Case, Ryan; Murawsky, Christopher M.; Estes, Bram; Moore, Gregory L.; Bernett, Matthew J.; Muchhal, Umesh; Desjarlais, John R.; Staley, Binnaz K.; Stevens, Jennitte; Cooke, Keegan S.; Aeffner, Famke; Thomas, Oliver; Stieglmaier, Julia; Lee, Jae-Lyun; Coxon, Angela; Bailis, Julie M.

doi:10.1158/2159-8290.24988644.v1

cd-23-0984_supplementary_figure_s4_suppsf4.pdf (493.61 kB)

Supplementary Figure S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer

journal contribution

posted on 2024-01-12, 08:21 authored by Olivier Nolan-Stevaux, Cong Li, Lingming Liang, Jinghui Zhan, Juan Estrada, Tao Osgood, Fei Li, Hanzhi Zhang, Ryan Case, Christopher M. Murawsky, Bram Estes, Gregory L. Moore, Matthew J. Bernett, Umesh Muchhal, John R. Desjarlais, Binnaz K. Staley, Jennitte Stevens, Keegan S. Cooke, Famke Aeffner, Oliver Thomas, Julia Stieglmaier, Jae-Lyun Lee, Angela Coxon, Julie M. Bailis

STEAP1 expression in mCRPC cell lines and tumor samples

Funding

n/a

History

ARTICLE ABSTRACT

The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in most prostate tumors and at increased levels in metastatic castration-resistant prostate cancer (mCRPC). We developed a STEAP1-targeted XmAb 2+1 T-cell engager (TCE) molecule, AMG 509 (also designated xaluritamig), that is designed to redirect T cells to kill prostate cancer cells that express STEAP1. AMG 509 mediates potent T cell–dependent cytotoxicity of prostate cancer cell lines in vitro and promotes tumor regression in xenograft and syngeneic mouse models of prostate cancer in vivo. The avidity-driven activity of AMG 509 enables selectivity for tumor cells with high STEAP1 expression compared with normal cells. AMG 509 is the first STEAP1 TCE to advance to clinical testing, and we report a case study of a patient with mCRPC who achieved an objective response on AMG 509 treatment. Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and lack of tumor-specific targets. AMG 509 provides a targeted immunotherapy approach to engage a patient's T cells to kill STEAP1-expressing tumor cells and represents a new treatment option for mCRPC and potentially more broadly for prostate cancer.See related commentary by Hage Chehade et al., p. 20.See related article by Kelly et al., p. 76.This article is featured in Selected Articles from This Issue, p. 5